Patheon — Q4 2005 Earnings Presentation
19 slides from Patheon's earnings presentation, Dec 14, 2005
Slide 1: Q4 2005 Financial Results Conference Call
Q4 2005 FINANCIAL RESULTS CONFERENCE CALL December 14, 2005 11:30 a.m. (EST) Forward-looking Information This presentation contains forward-looking statements with respect to the Company, including its business operations and strategy and financial performance and condition. Although management beli
Slide 2: Presenting on Behalf of Patheon / Agenda
Presenting on Behalf of Patheon Robert Tedford – Chief Executive Officer Rodger Roden – Chief Financial Officer Nick DiPietro – President and Chief Operating Officer Clive Bennett – President and Chief Operating Officer, MOVA Dr. Shabbir Anik – President, PDS and Chief Scientific Officer Agenda
Slide 3: Opening Comments
Opening Comments Strategic accomplishments in 2005 Creation of ceph lyo capability in Swindon Completion of lyo expansion program in Italy Large-volume parenteral start-up in Ferentino Product carve-outs (2) Opening Comments Operating highlights in 2005 Excellent year in base business 17%
Slide 4: Financial Highlights: Q4 and Fiscal 2005
Opening Comments Disappointments in 2005 MOVA results Significantly lower-than-anticipated volumes in connection with a new product launch at Whitby FINANCIAL HIGHLIGHTS Q4 and Fiscal 2005 Q4 2005 Webcast Presentation 4
Slide 5: Q4 2005 Highlights and Revenue Growth
Q4 2005 Highlights Revenues up 48% to $182M Internal growth of 15% ($18M) Strategic growth from MOVA of $41M EBITDA almost doubled to $26M EBITDA margin of 14.4% vs. 12.8% before one-time items Net earnings increased 17% to $5M*; EPS of 5.8* cents vs. 8.9* cents a year ago Reported net
Slide 6: EBITDA and EBITDA Margin
EBITDA and EBITDA Margin FY 2005 (%) 13.6% 14.0% 14.1% 14.5% 14.4% 12.9% 12.2% 12.8% * 13.2% 11.2% * * 11.3% 10.2% 10.3% FY FY FY FY FY Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 '01 '02 '03 '04 '05 '04 '04 '04 '04 '05 '05 '05 '05 EBITDA up 104% to $98M EBITDA margin improvement to 14.0% in 2005 (11.2%* in 2004) r
Slide 7: Reported Net Earnings and EPS
Reported Net Earnings and EPS FY 2005 Reported net earnings of $22M vs. $11M a year ago Reported net earnings in 2005 after the following non-recurring items: i) $3M gain on the sale of land reported in Q4 ii) $1M write off of deferred finance costs reported in Q1 Reported EPS of 24.9 cents vs
Slide 8: Depreciation and Amortization; Interest and Tax Rate
Depreciation and Amortization FY 2005 Depreciation expense of $33M, an increase of $10M or 47% $7M attributable to incremental depreciation of MOVA assets $1.6M attributable to translation to US$ of Canadian and EU depreciation Balance related to capital programs at sites in Italy, Toronto, Cinc
Slide 9: New Financing Arrangements / Operations Overview
New Financing Arrangements Post Q4, commitments from banking syndicate for $290M in new credit facilities: 5-year term for $50M 6-year term for $165M Revolver of $75M Will replace MOVA debt and one-year bridge facility One-time write-off of deferred financing costs and pre- payment penalties o
Slide 10: Revenue Growth
Revenue Growth Q4 2005 North American revenues grew $50M or 65% Internal growth of $9M or 12% driven by new product launches and strong PDS growth MOVA contribution of $41M, up from $39M in Q3 volumes lower than expected due to voluntary suspension of Omnicef® powder production in connection w
Slide 11: North America and Europe
North America FY 2005 North American revenues grew 67% ($197.9M) Incl. MOVA, Rx revenues up 121%, PDS up 37%, OTC up 7% NA internal growth: Rx revenues up 20%, PDS up 26%, OTC up 7% growth in Rx volumes from newly launched products excellent PDS growth on a higher base, reflecting progress at C
Slide 12: Update on MOVA / Capital Investment in Europe
Capital Investment in Europe FY 2006 Swindon, U.K. new facility dedicated to lyophilized cephalosporins investment of approx. €22M in 2006, substantial financing provided by client complements existing sterile cephalosporin capabilities at Swindon and oral cephalosporin capabilities at Carolina
Slide 13: Update on FDA Warning Letter
Update on FDA Warning Letter Warning Letter received September 16, 2005 15 days to respond Voluntary suspension of manufacturing to resolve issues Response letter with many commitments submitted on time Response accepted by FDA one week later Update on FDA Warning Letter Full production resume
Slide 14: Review of FY 2005 and Areas of Focus in 2006
Review of FY 2005 MOVA 2005 financial results impacted by: Client-supplied API shortage issue for Omnicef® resolved at the end of Q3 2005 FDA Warning Letter now resolved; impact on Q4 of 2 cents Trade inventory adjustments for newly launched product, which reduced client demand in second half V
Slide 15: Update on PDS: PDS Revenue Growth
Update on PDS PDS Revenue Growth FY 2005 Global PDS revenues up 38% YOY to $91.1M North American revenues grew 37% to $73.1M Solid performance in Canada Excellent growth in Cincinnati European revenues grew 46% to $17.9M Momentum at Swindon Progress at start-up operation in Ferentino Q4 2005
Slide 16: PDS Strategic Update
PDS Strategic Update Five Centres of Excellence on two continents Canada (Toronto/Whitby/York Mills); Cincinnati, MOVA, Swindon, Ferentino Strong PDS leadership at each Centre of Excellence Directors at Swindon, Ferentino and MOVA added in 2005 500+ development scientists and technical staff
Slide 17: Four Product Launches in 2005; The Year Ahead in PDS
Four Product Launches in 2005 2001 to 2005 Approved PDS Commercialization 15* launches since 2001 Including 8 launches in 2004/2005 *14 as at October 31, 2005; one subsequent to year end The Year Ahead in PDS Demand for PDS services expected to remain strong favourable biotech financing environmen
Slide 18: Outlook
OUTLOOK Outlook Consolidated 2006 results Expect 2006 results to stabilize; growth and profitability expected to improve in 2007 Expect modest improvement in 2006 operating results: Second half stronger than first half Net earnings and EPS similar to 2005 levels excluding one-time gain and antic
Slide 19: Outlook: Q1 2006 Results and 2006 Transition Year
Outlook Q1 2006 Results Will reflect negative impact of: Normal seasonality and production shutdowns Lower Omnicef® production levels (3¢ EPS) Write-off of deferred financing costs and prepayment penalties ($7.6M) Full quarter of MOVA-related charges (amortization, depreciation and interest) vs